Actuate Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ACTU Nasdaq 2836 actuatetherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Actuate Therapeutics, Inc.

Actuate Announces Scientific Reports Publication on Elraglusib’s Novel Immunomodulatory Mechanism of Action as a GSK-3β Inhibitor - Sep 23rd, 2024 12:00 pm
Actuate Announces Upcoming Presentation on Initial Data on Elraglusib in Combination with FOLFIRINOX at the AACR Special Conference on Advances in Pancreatic Cancer Research - Sep 16th, 2024 12:00 pm
Actuate Receives FDA Orphan Drug Designation for Elraglusib for Treatment of Soft Tissue Sarcomas - Sep 11th, 2024 12:00 pm
Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma - Sep 9th, 2024 12:00 pm
Actuate to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Sep 5th, 2024 1:10 pm
Actuate Therapeutics to Ring the Nasdaq Opening Bell on Friday, August 23, 2024 - Aug 20th, 2024 1:00 pm
Actuate Therapeutics Announces Closing of Initial Public Offering - Aug 14th, 2024 8:05 pm
Actuate Therapeutics Announces Pricing of Initial Public Offering - Aug 13th, 2024 12:27 am
Actuate Therapeutics Files Registration Statement for Initial Public Offering - May 28th, 2024 11:00 am